Gastrointestinal Stents Market

Gastrointestinal Stents Market Outlook (2025 to 2035)

The global gastrointestinal stents market is projected to grow steadily over the next decade, rising from an estimated value of USD 567.8 million in 2025 to USD 1,201.5 million by 2035, growing at a strong CAGR of 7.8%. It is driven by the worldwide rise in gastrointestinal conditions, increasing demand for minimally invasive interventions, and growing geriatric populations with enhanced vulnerability to gastrointestinal complications. They are becoming standard in endoscopic treatment approaches, providing non-surgical interventions for the management of malignant and benign gastrointestinal tract obstructions.

Biliary stents, a leading segment in the gastrointestinal stents market, are anticipated to experience rapid adoption, driven by their use for the treatment of biliary strictures and obstructive jaundice. The segment is aided by improvements in self-expanding metal stents (SEMS) and the launch of biodegradable variants, which decrease the requirement for secondary interventions. With clinical emphasis intensifying on enhancing quality of life and shortening hospitalization, biliary and duodenal stents are being increasingly employed as first-line treatments.

North America is likely to continue to be at the forefront because of early technology adoption, universal access to healthcare infrastructure, and a large procedural volume. Europe will come in a close second due to innovation in stent design and product development for sustainability. The Asia-Pacific region will grow at the highest rate due to increasing medical infrastructure, favorable government initiatives, and rising training of gastroenterology experts.

Cooperation among medical device companies and healthcare professionals is speeding up product innovation, while collaboration with academe-led research institutions is enhancing the clinical effectiveness of new devices. Furthermore, digital integration-like AI-assisted stent placement-is facilitating more secure, quicker, and more accurate procedures, attracting patients and providers alike in search of maximized outcomes.

During the forecast period, the gastrointestinal stents market will be influenced by technology uptake, regional manufacturing growth, and favorable regulatory policies. Firms that adopt innovation in product development and clinical use will lead the fast-evolving industry.

Key Metrics

Metric	Value
Estimated Global Size in 2025	USD 567.8 million
Projected Global Size in 2035	USD 1,201.5 million
CAGR (2025 to 2035)	7.8%

Fact.MR Survey for Industry Dynamics Based on Stakeholder Perspectives

The gastrointestinal stents market of 2025 to 2035 is transforming by a convergence of technological advancements, regional regulatory dynamics, and stakeholder-led agendas, as per Fact. MR's survey, 78% of gastroenterologists give priority to minimally invasive procedures, driving stent-based treatments ahead of surgeries.

Manufacturers are developing next-generation biodegradable and biocompatible stents to minimize complications and meet sustainability requirements, particularly in Europe. At the same time, cost-effectiveness and insurance coverage continue to be determinants of public health system uptake.

Technology integration is region-specific, with North America leading the way with AI-based imaging systems for accurate placement, followed by Europe with its thrust on green materials and hybrid systems. Asia-Pacific is behind in terms of training constraints and the absence of regional manufacturing centers, but efforts to decentralize supply chains are gaining momentum.

Supply chain limitations, such as dispersed supplier bases and regulatory hurdles, are universal drawbacks. Nevertheless, businesses everywhere are aligning investments toward AI-based diagnostics, green-compliant stents, and local manufacturing centers.

Government policies also influence regional dynamics. The USA is supportive of fast-track approvals, the EU has stringent biocompatibility standards, and nations such as China and India are advocating local manufacturing. Industry participants need to improve compliance measures, invest in AI and imaging technology, and develop region-specific manufacturing capabilities to survive. Fact.MR analysis indicates that early movers on these imperatives will dominate chronic care solutions and value-based healthcare delivery.

Shifts in the Market from 2020 to 2024 and Future Trends 2025 to 2035

Between 2020 and 2024, the gastrointestinal stents market grew dramatically due to a rising number of gastrointestinal cancers and conditions such as strictures and obstructions. The demand for minimally invasive treatments was on the rise, and this translated into higher stent usage in palliative and therapeutic treatment.

Endoscopic techniques improved significantly, with more precise stent placement and shorter patient recovery periods. Advances in stent technology, including biodegradable and self-expanding stents, also gained popularity during this period in favor of improved patient comfort and procedure outcomes.

From 2025 to 2035, the gastrointestinal stents market will transition toward more technologically superior and personalized solutions. Smart stents with implantable sensors will become more prevalent, allowing real-time pressure or flow monitoring and fewer complications.

AI-assisted endoscopic deployment will increase accuracy and decrease procedural complications. Responsiveness of stents to anatomy and disease progression, invasiveness reduction, and long-term compatibility improvement will be further enhanced. Sustainability and biocompatibility in material will also propel future advancements as part of wider healthcare trends.

Comparative Market Shift Analysis 2020 to 2024 vs. 2025 to 2035

2020 to 2024	2025 to 2035
Growing application due to mounting gastrointestinal cancers and obstructions	Growth due to personalized, smart, and adaptive stent technologies
Rising adoption of minimally invasive endoscopic processes	AI-positioning and real-time monitoring through sensor-equipped stents
Deployment of self-expanding metal and plastic stents for improved results	Biocompatible, bioabsorbable stents designed for patient anatomy
Technological advances in the endoscopic delivery system	Emergence of high-end imaging and robotics for more precision
Emphasis on minimizing hospitalization and enhancing patient comfort	Focus on long-term stent performance and material durability

Country-wise Analysis of the Gastrointestinal Stents Market 2025 to 2035

Country	CAGR (2025 to 2035)
USA	6.3%
UK	5.6%
France	5.3%
Germany	5.5%
Italy	5.1%
South Korea	5.9%
Japan	5.2%
China	7.0%
Australia-NZ	5.4%

The USA

The USA gastrointestinal stents market will grow at 6.3% CAGR throughout the study. The USA gastrointestinal stents market will grow steadily with the high incidence of gastrointestinal cancers and the strict compliance to minimum invasive surgical protocols. Sophisticated healthcare facilities and the rapid uptake of next-generation stents like biodegradable and drug-eluting stents continue to fuel the sales penetration.

The increasing aged population, growth in obesity levels, and recurrent gastrointestinal disorders such as colorectal cancer and Crohn's disease are fueling the demand for both therapeutic and palliative stenting. Increased procedural innovation with endoscopy and image-guided interventions' integration also augments success rates, thus generating increased acceptance.

The major competitors in the United States are also making investments in clinical trials and approval for personalized stents, again boosting competition. Insurance coverage for endoscopic procedures and increasing outpatient endoscopy centers contribute to procedural volume, positively influencing industry dynamics.

UK

The UK gastrointestinal stents market is expected to grow at 5.6% CAGR during the study period. In the UK, the gastrointestinal stents market is gaining traction due to rising colorectal and esophageal cancer cases, along with greater reliance on endoscopic solutions for palliative care.

The shift in the healthcare system toward minimally invasive procedures has witnessed an explosion in gastrointestinal stenting procedures, mostly in tertiary facilities. Gastroenterology and interventional endoscopy advanced training programs are preparing practitioners to manage complex situations with self-expanding metal stents. Further, increased partnerships between hospitals and technology manufacturers have resulted in imaging systems being brought onto the same platform as stent deployment tools, improving procedure precision.

National health policies aimed at early detection of cancer and tailor-made care pathways also reinforce the broader utilization of stents. Cost-effectiveness, reduced recovery times, and better quality of life for patients who receive palliative care are set to drive greater clinical uptake.

France

France's gastrointestinal stents market will grow at 5.3% CAGR through the period of study. France is poised to experience slow growth in the gastrointestinal stents market, supported by an intense awareness of cancer of the digestive tract and the prevalent use of endoscopic diagnostics. Proactive screening by the public health sector for gastric and colorectal cancers allows early detection and timely stent intervention.

The implementation of gastrointestinal stenting as a routine treatment in malignant and benign strictures is widening the scope of the industry. Increased lifestyle-based gastrointestinal diseases are another significant contributor, driving increased procedure volumes in specialist facilities.

French medical device regulations also facilitate the introduction of new stent technologies with improved expansion force and lower migration risk. In addition, multidisciplinary treatment models with gastroenterologists, oncologists, and radiologists are enhancing procedural coordination, thus improving clinical success rates.

Germany

The German gastrointestinal stents market will grow by 5.5% CAGR over the study period. Germany's gastrointestinal stents market will continue to grow steadily with its highly developed medical infrastructure and strong demand for technologically advanced treatments. A robust availability of endoscopy units in hospitals and an aging demographic profile support growing cases of gastrointestinal stenting.

The nation is also at the forefront of clinical research, which facilitates the use of next-generation stents for intricate esophageal, duodenal, and biliary blockages. The reimbursement system in Germany and quality certification foster hospitals to acquire high-quality stents with established biocompatibility and performance.

Moreover, hospital stay reduction efforts and support for day-care procedures are congruent with the minimally invasive method of stent placements. The increasing emphasis on palliative oncology and comfort care also supports stent use for symptom control in inoperable cancers.

Italy

Italy's gastrointestinal stents market is likely to expand by 5.1% CAGR over the forecast period. Italy is expected to experience moderate growth in the gastrointestinal stents market due to rising cancer awareness and steady modernization of its diagnostic care environment. Although adoption has been slower in certain areas because of healthcare budget constraints, early cancer screening is enhanced by national programs that augment procedural use in metropolitan hospitals.

Italian healthcare centers are progressively adopting interventional gastroenterology services that encompass gastrointestinal stenting to treat obstructing malignancies and strictures. The movement away from traditional surgeries towards endoscopic options should fuel future demand.

Technological advancements in biodegradable and anti-reflux stents are attracting interest among Italian physicians, enhancing therapeutic results in high-risk patients. Partnerships with EU-based medical technology companies are facilitating the introduction of cutting-edge stenting systems in top-tier hospitals and academic institutions.

South Korea

The South Korean gastrointestinal stents market will grow at 5.9% CAGR over the study period. South Korea is expected to witness tremendous growth in the gastrointestinal stents market because of its preventive culture and high rate of adoption of technology. The country's strong digital health infrastructure and high penetration of state-of-the-art endoscopic instruments increase procedural accessibility and efficiency.

An aging population and increased rate of stomach and colorectal cancers are encouraging increased dependence on stenting procedures as palliative and curative treatments. South Korea's hospitals are actively adopting AI-enabled endoscopy and stent customization to enhance procedural precision and patient comfort.

Government initiatives for healthcare digitization are enhancing coordination between care settings and driving procedural volumes. Moreover, favorable insurance schemes and local manufacture of cost-effective medical devices increase the availability and affordability of stents, particularly in secondary hospitals.

Japan

Japan's gastrointestinal stents market is anticipated to grow at 5.2% CAGR throughout the study. Japan's gastrointestinal stents market is expected to rise steadily, supported by Japan's high incidence of digestive cancers and high-end hospital capabilities. Stenting for palliative treatment of obstructive gastrointestinal tumors is well-established, particularly in older people.

Japanese hospitals have a precision medicine model that prefers the use of stents with personalized size and design to minimize migration and enhance placement success. Japanese research institutions are also contributing to stent coating and bioengineered material innovation to advance long-term safety.

The increasing trend toward outpatient procedures for non-surgical therapy aligns with the use of minimally invasive stents. Integration with high-end imaging platforms and robotic support is further enhancing procedural success and patient satisfaction.

China

The Chinese gastrointestinal stents market will grow at 7.0% CAGR over the study period. China is likely to be the fastest-growing gastrointestinal stents market, driven by increasing cancer incidence, accelerated hospital growth, and significant health reform efforts. The government's initiative to improve diagnostic infrastructure in rural and urban areas is facilitating increased access to gastrointestinal procedures.

Enhanced investment in healthcare and increased use of digital and AI-driven endoscopic equipment are speeding up stent implantation for both malignant and benign gastrointestinal disorders. With colorectal cancer being one of the most common diseases in the nation, stenting has emerged as a key part of non-surgical therapy.

Local production ability also lowers costs, making products more affordable and accessible to larger industries. The collaboration of multinational companies with local hospitals is introducing new-generation stents with improved features such as drug-elution and anti-tumor capabilities in order to deliver better patient results.

Australia-NZ

Australia-New Zealand's gastrointestinal stents market is set to expand by 5.4% CAGR throughout research. Australia and New Zealand are projected to witness persistent growth in the gastrointestinal stents market as a result of the extensive adoption of cutting-edge medical technology and enhanced access to healthcare. Hospitals in both nations favor less invasive treatment options for gastrointestinal obstructions, supporting the application of stents as a favored treatment.

Colorectal and gastric cancer continue to fuel clinical demand, and rising stent applications for palliative and pre-surgical decompression are noted. Public campaigns favoring early diagnosis and widening private diagnostic facilities are driving volumes of procedures.

Tele-endoscopy and mobile stenting units, which are clinically integrated, reduce disparities in access across rural and underserved areas. A sustained focus on the training of endoscopy specialists and embracing international treatment standards also adds to clinical effectiveness and extended stent use.

Segment-wise Analysis

By Stent Type

By stent type, the gastrointestinal stents market is segmented into metal stents, which will dominate with 69.1%, while plastic stents will cover 30.9%.

Metal stents are generally made from materials such as stainless steel or nitinol. They are widely accepted for their gaining pressure, a lot of flexibility, and a long support life in patients with malignant gastrointestinal obstruction symptoms. These stents are typically very preferred in difficult conditions, such as with esophageal, duodenal, and colonic cancers, which are either persistent or recurrent obstruction.

There are a number of leading companies, such as Boston Scientific and Cook Medical, with exciting metal stents, for example, the WallFlex® stent by Boston Scientific, which is designed to provide increased radial force for the prevention of stent migration, so these are prevalent in palliative care. Performance and timeliness of metal stents and advances in stent design, such as fully covered and drug-eluting stents, together propel their greater adoption by high-risk patients who face the need for prolonged care

Plastic stents, on the other hand, are projected to hold a 30.9% share in 2025. They are less expensive and are primarily used for short-term applications such as biliary obstructions or less complicated patients. Because plastic stents are cheaper and easier to place, they are often used as outpatient or temporary measures.

Although Medtronic and Cook Medical produce plastic stents, these are frequently used in minimally invasive procedures. However, these plastic stents are not as durable as the metals, so they do not provide long-term treatment options.

By Product

In 2025, biliary stents will hold a share of 31.4%, while esophageal stents will take 24.2% of the gastrointestinal stents market.

Biliary stents are primarily employed in the remedy of obstruction of the bile duct, which can give rise from malignancy or by a so-called gallstone or stricture. This has to be installed to relieve blocked bile flow from the liver to the small intestine. It is anticipated that by 2025, the increasing incidence of such conditions as cholangiocarcinoma and pancreatic cancers will boost the demand for biliary stents.

Major players like Boston Scientific and Medtronic have developed a comprehensive portfolio of biliary stents, such as fully covered and drug-eluting, to improve patient outcomes with low stent occlusion rates. These stents are preferred because of their superiority in the long term for high-risk patients.

Holding a share of 24.2%, esophageal stents are usually used to treat an esophageal obstruction caused by malignancies, strictures, or otherwise. These stents provide necessary support to the esophagus to prevent further narrowing or collapse of the esophageal lumen.

Some of the esophageal stents are specially designed for benign and malignant obstructions and are available from brands like Cook Medical and Merit Medical. Increasing incidences of esophageal cancers are foreseen to further boost demand for these stents, especially in the regions with high consumption of both smoking and alcohol.

Competitive Outlook

The gastrointestinal stents market is highly competitive, marked by technological advancement, device miniaturization, and a growing preference for minimally invasive procedures. A mix of global MedTech leaders and specialized regional firms shapes industry dynamics. While competition is influenced by product reliability and regulatory compliance, manufacturers now also differentiate through the integration of real-time imaging compatibility and anti-migration designs, responding to complex clinical demands in palliative and curative GI procedures.

Boston Scientific Corporation, Cook Medical, and Taewoong Medical Co. Ltd. are at the forefront. They hold a significant share in the gastrointestinal stents market due to their innovation pipelines and diverse stent offerings. Boston Scientific maintains dominance through advanced covered metal stents with drug-eluting properties, while Cook Medical focuses on dual-layer constructions to improve flexibility and patient comfort. Taewoong, known for design precision, continues to expand globally with customized solutions for biliary, duodenal, and esophageal conditions.

Becton, Dickinson and Company (via C.R. Bard Inc.), and Olympus Corporation have emerged as strong competitors by blending stent technology with endoscopic visualization tools. BD integrates smooth delivery systems for optimal placement, whereas Olympus leverages endoscopy expertise to enable stent placement with high procedural accuracy. Both target procedural efficiency in outpatient and low-resource settings.

Strategic developments include regional partnerships and product line extensions. W.L. Gore emphasizes anti-migration stent meshes with biodegradable coatings, while Merit Medical and ELLA-CS are investing in niche designs for pediatric and anatomically complex cases. As procedural volume grows in Asia-Pacific and Latin America, companies are scaling distribution and localization to enhance responsiveness and comply with varying clinical regulations.

Market Share Analysis by Company

Company Name	Estimated Market Share (%)
Boston Scientific Corporation	20-23%
Cook Medical	15-18%
Taewoong Medical Co. Ltd.	12-15%
Becton, Dickinson and Company	10-13%
Olympus Corporation	8-10%
Other Companies Combined	23-30%

Key Company Insights

Boston Scientific Corporation (20-23%)

Boston Scientific leads with its premium stent range, including drug-eluting and covered metal variants designed for superior patency and compatibility with advanced endoscopic systems.

Cook Medical (15-18%)

Cook Medical’s dual-layered stents are valued for their superior flexibility and low migration rates, supporting patient-centric outcomes in complex GI disorders.

Taewoong Medical Co. Ltd. (12-15%)

Taewoong has built a strong global presence with anatomically specific GI stents, known for precision engineering and a growing reputation in emerging markets.

Becton, Dickinson and Company (10-13%)

BD integrates Bard’s stenting legacy with innovation in delivery technologies, enhancing procedural accuracy and adoption in both high- and low-resource healthcare systems.

Olympus Corporation (8-10%)

Olympus maximizes synergies between its visualization systems and GI stents, offering physicians an integrated toolkit for improved navigation and deployment efficiency.

Key Players

• Boston Scientific Corporation
• Becton, Dickinson and Company
• C.R. Bard Inc.
• W.L. Gore & Associates Inc.
• Cook Medical
• Taewoong Medical Co. Ltd.
• Merit Medical Systems Inc.
• ELLA-CS, s.r.o
• CONMED Corporation
• Olympus Corporation
• S&G Biotech Inc
• Other regional and endoscopic device firms

Segmentation

• By Stent Type:

  • Metal Stents
  • Plastic Stents

• By Product:

  • Biliary Stents
  • Duodenal Stents
  • Colonic Stents
  • Pancreatic Stents
  • Esophageal Stents

• By End User:

  • Hospitals
  • Clinics
  • Ambulatory Surgery Centers
  • Others

• By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Middle East and Africa (MEA)